首页> 美国卫生研究院文献>Journal of Applied Clinical Medical Physics >Dosimetric validation of Monaco treatment planning system on an Elekta VersaHD linear accelerator
【2h】

Dosimetric validation of Monaco treatment planning system on an Elekta VersaHD linear accelerator

机译:Elekta VersaHD直线加速器对摩纳哥治疗计划系统进行剂量学验证

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

The purpose of this study is to perform dosimetric validation of Monaco treatment planning system version 5.1. The Elekta VersaHD linear accelerator with high dose rate flattening filter‐free photon modes and electron energies was used in this study. The dosimetric output of the new Agility head combined with the FFF photon modes warranted this investigation into the dosimetric accuracy prior to clinical usage. A model of the VersaHD linac was created in Monaco TPS by Elekta using commissioned beam data including percent depth dose curves, beam profiles, and output factors. A variety of 3D conformal fields were created in Monaco TPS on a combined Plastic water/Styrofoam phantom and validated against measurements with a calibrated ion chamber. Some of the parameters varied including source to surface distance, field size, wedges, gantry angle, and depth for all photon and electron energies. In addition, a series of step and shoot IMRT, VMAT test plans, and patient plans on various anatomical sites were verified against measurements on a Delta4 diode array. The agreement in point dose measurements was within 2% for all photon and electron energies in the homogeneous phantom and within 3% for photon energies in the heterogeneous phantom. The mean ± SD gamma passing rates of IMRT test fields yielded 93.8 ± 4.7% based on 2% dose difference and 2 mm distance‐to‐agreement criteria. Eight previously treated IMRT patient plans were replanned in Monaco TPS and five measurements on each yielded an average gamma passing rate of 95% with 6.7% confidence limit based on 3%, 3 mm gamma criteria. This investigation on dosimetric validation ensures accuracy of modeling VersaHD linac in Monaco TPS thereby improving patient safety.
机译:本研究的目的是对Monaco治疗计划系统5.1版进行剂量学验证。在这项研究中使用了具有高剂量率平坦化无滤波器光子模式和电子能量的Elekta VersaHD线性加速器。新敏捷头的剂量输出与FFF光子模式相结合,保证了在临床使用之前对剂量精度的调查。 Elekta在摩纳哥TPS中使用委托的光束数据(包括百分比深度剂量曲线,光束轮廓和输出因子)创建了VersaHD直线加速器的模型。在摩纳哥TPS上的塑料水/泡沫聚苯乙烯幻影组合体上创建了各种3D保形场,并针对经校准的离子室进行的测量进行了验证。一些参数变化,包括所有光子和电子能量的源到表面距离,场大小,楔形,龙门角度和深度。此外,针对Delta 4 二极管阵列上的测量结果,验证了一系列解剖位置的IMRT,VMAT测试计划和患者计划。对于均质体模中的所有光子和电子能量,点剂量测量的一致性在2%以内,对于异质体模中的光子能量,在3%以内。根据2%的剂量差异和2毫米的商定距离标准,IMRT测试场的平均±SD伽玛通过率得出93.8±4.7%。在摩纳哥TPS中重新规划了八份先前治疗的IMRT患者计划,每项五次测量得出的平均伽玛通过率达到95%,基于3%,3毫米伽玛标准的置信极限为6.7%。这项剂量学验证研究确保了在摩纳哥TPS中对VersaHD直线加速器建模的准确性,从而提高了患者安全性。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号